The pivot to crypto is a fundamental strategic shift likely to be viewed negatively by pharma-focused investors. Monitor for further filings on the DAT 2.0 launch, any crypto purchases, and the structure of the judgment assignment. Expect increased volatility and potential dilution.
Price Chart
Executive Summary
Bio-Path is abandoning its pharmaceutical focus to launch a Digital Asset Treasury 2.0 (DAT 2.0) using AI for crypto trading, approved by the Board. It also assigned up to $10M of CEO Vikram Grover's $57.9M judgment to the company in exchange for equity/notes. The reverse split was canceled. This radical pivot to speculative crypto activities signals desperation and likely dilution, with no pharma revenue or product progress.
Key Facts
- Board approved launch of DAT 2.0, an AI-driven digital asset treasury for crypto trading on multiple blockchains.
- Board approved opening a Coinbase account for buying, selling, and holding cryptocurrencies.
- Canceled the previously approved 1-30 reverse stock split.
- Board assigned up to $10M of CEO Vikram Grover's $57.9M judgment (plus interest) to the company in exchange for Notes, Preferred Stock, or Common Shares.
- The judgment is from a December 2023 court case against Net Savings Link, Inc. (NSAV).
- No assurances the judgment will be monetized or that Grover will obtain custodianship.
- The company repositioned from pharmaceutical to digital asset management, adding scientific advisors and engaging strategic/financial advisors.
Financial Impact
Up to $10,000,000 of a $57,903,750 judgment assigned to the company, consideration in Notes/Preferred/Common at undetermined prices; no current revenue or funding details provided.
Risk Factors
- Abandonment of core pharma pipeline risks total loss of existing business value.
- Crypto trading involves extreme price volatility and regulatory risk.
- Judgment assignment is contingent and may never materialize, leading to dilution without value.
- OTC Pink listing and low market cap amplify risk of sharp sell-offs.
- No revenue or product milestones provided; reliance on speculative crypto income.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001663577-26-000170 |
| Exhibit: ex10_1.htm | 0001663577-26-000170 |
| Exhibit: ex10_2.htm | 0001663577-26-000170 |
| Document: 0001663577-26-000170-index-headers.html | 0001663577-26-000170 |
| Document: 0001663577-26-000170-index.html | 0001663577-26-000170 |
| Document: 0001663577-26-000170.txt | 0001663577-26-000170 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 16, 2026 14w ago | 8-K | $0.0400 $0.000200 | ▲ +99.50% | ▲ +103.47% | $0.000300 (+99.25%) |
May 26, 2026 21w ago | 8-K | $0.0400 $0.0339 | ▲ +15.25% | ▲ +17.97% | $0.000300 (+99.25%) |
Feb 24, 2026 34w ago | 8-K | $0.0700 $0.0200 | ▼ −71.43% | ▼ −78.18% | $0.000300 (−99.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers